Add
headlines to your
personalized My Yahoo! Page
(
About
My Yahoo! and RSS )
MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation
Reiterated In Research Note By Investrend Affiliate SISM Research,
Indicating Greater Market Potential And Citing Recent Superior
Performance of Stent Coating Technologies In Recent Tests NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior
analyst with Investrend affiliate SISM Research and a four star
analyst according to StarMine, has reiterated his "Buy/4" Rating and
$2.50 12-month Target Valuation for MIV Therapeutics, Inc. (OTCBB: MIVT - News) in a Research Note.
"Just last Wednesday, MIVT announced remarkable results from preclinical studies of two of its novel biocompatible polymer-free drug-eluting stent coating technologies that matched or even outperformed Cordis' and Boston Scientific's drug eluting stents. The independently conducted four-week porcine study at the Erasmus University Medical Center in the Netherlands compared stents coated with MIVT's polymer-free drug-eluting technologies to the industry's benchmark, the J&J Cypher stent, one of the world's best selling drug-eluting stents. Three variations of MIVT's polymer-free Sirolimus eluting coatings were at least as effective as -- and in some cases, better -- than Johnson & Johnson's Cypher drug-eluting cardiovascular stents. Based on these results, MIVT will begin preparations for human implantation. "MIV Therapeutics is developing a diverse suite of polymer-free HAp coating formulas... "The drug-eluting stent market grew from zero to $5.3 billion in three years and has captured 85% of the US stent market. To date, more than nine million DES devices have been inserted. In 2005, about 1.5 million patients were implanted with drug-eluting stents in the US alone... "Despite a stock price increase of more than 50% since last Wednesday, in our view, MIVT, at a market cap of only $35 million, is still massively undervalued... MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage." SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM writes, publishes and distributes research coverage on micro- to small-cap public companies trading on the OTC, NASDAQ and AMEX. This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall and Investext, to Reuters Multex, and Investrend. The full report, including important disclosures and disclaimers, is available at http://www.sism.com, http://www.investrendresearch.com, and at the company's InvestorPower Page accessible from http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company. Both SISM Research and Investrend Research subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and MIVT's research will be enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com). Anyone interested in receiving alerts regarding MIV Therapeutics research should email contact@investrend.com with "MIVT" in the subject line. Contact: MIV Therapeutics, Inc. Investor Relations 604-301-9545 x14 Toll-free: 800-221-5108 http://www.mivtherapeutics.com/ or Investrend Research Div. Investrend Communications, Inc. R. Hempel, 718-896-5060 contact@investrend.com www.investrendresearch.com Source: MIV Therapeutics, Inc.
|  |
RSS Feeds | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||